The role of CETP inhibition in dyslipidemia

Karim El Harchaoui; Wim A. van der Steeg; Erik S. G. Stroes; John J. P. Kastelein

The role of CETP inhibition in dyslipidemia

Karim El Harchaoui, Wim A. van der Steeg, Erik S. G. Stroes, John J. P. Kastelein

Research output: Contribution to journal › Article › Academic › peer-review

14 Citations (Scopus)

Abstract

Cholesteryl ester transfer protein (CETP) inhibitors are currently being investigated because of their ability to increase high-density lipoprotein cholesterol levels. In various metabolic settings, the relationship between CETP and lipoprotein metabolism is complex and may depend largely on the concentration of triglyceride-rich lipoproteins. Two CETP inhibitors, JTT-705 and torcetrapib, are in an advanced phase of development. Following hopeful intermediate results, a large endpoint study using torcetrapib has just been discontinued due to increased mortality in torcetrapib-treated subjects. In this review we summarize clinical data on the use of CETP inhibitors

Original language	English
Pages (from-to)	125-133
Journal	Current Atherosclerosis Reports
Volume	9
Issue number	2
Publication status	Published - 2007

Cite this

@article{0365818365c6417ea88a6600468b5f1d,

title = "The role of CETP inhibition in dyslipidemia",

abstract = "Cholesteryl ester transfer protein (CETP) inhibitors are currently being investigated because of their ability to increase high-density lipoprotein cholesterol levels. In various metabolic settings, the relationship between CETP and lipoprotein metabolism is complex and may depend largely on the concentration of triglyceride-rich lipoproteins. Two CETP inhibitors, JTT-705 and torcetrapib, are in an advanced phase of development. Following hopeful intermediate results, a large endpoint study using torcetrapib has just been discontinued due to increased mortality in torcetrapib-treated subjects. In this review we summarize clinical data on the use of CETP inhibitors",

author = "{El Harchaoui}, Karim and {van der Steeg}, {Wim A.} and Stroes, {Erik S. G.} and Kastelein, {John J. P.}",

year = "2007",

language = "English",

volume = "9",

pages = "125--133",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Current Medicine Group",

number = "2",

}

TY - JOUR

T1 - The role of CETP inhibition in dyslipidemia

AU - El Harchaoui, Karim

AU - van der Steeg, Wim A.

AU - Stroes, Erik S. G.

AU - Kastelein, John J. P.

PY - 2007

Y1 - 2007

N2 - Cholesteryl ester transfer protein (CETP) inhibitors are currently being investigated because of their ability to increase high-density lipoprotein cholesterol levels. In various metabolic settings, the relationship between CETP and lipoprotein metabolism is complex and may depend largely on the concentration of triglyceride-rich lipoproteins. Two CETP inhibitors, JTT-705 and torcetrapib, are in an advanced phase of development. Following hopeful intermediate results, a large endpoint study using torcetrapib has just been discontinued due to increased mortality in torcetrapib-treated subjects. In this review we summarize clinical data on the use of CETP inhibitors

AB - Cholesteryl ester transfer protein (CETP) inhibitors are currently being investigated because of their ability to increase high-density lipoprotein cholesterol levels. In various metabolic settings, the relationship between CETP and lipoprotein metabolism is complex and may depend largely on the concentration of triglyceride-rich lipoproteins. Two CETP inhibitors, JTT-705 and torcetrapib, are in an advanced phase of development. Following hopeful intermediate results, a large endpoint study using torcetrapib has just been discontinued due to increased mortality in torcetrapib-treated subjects. In this review we summarize clinical data on the use of CETP inhibitors

M3 - Article

C2 - 17877921

SN - 1523-3804

VL - 9

SP - 125

EP - 133

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

IS - 2

ER -